1. Murray, CJL, Lopez, AD. Disability: the invisible burden. In: Murray, CJL, Lopez, AD, eds. The Global Burden of Disease. Cambridge, MA: Harvard University Press; 1996:20-22.
Google Scholar2. McGrath, J, Saha, S, Chant, D, Welham, J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67-76. doi:10.1093/epirev/mxn001.
Google Scholar | Crossref | Medline | ISI3. Biological Sciences Curriculum Study . NIH Curriculum Supplement Series. Bethesda, MD: National Institutes of Health; 2007.
Google Scholar4. Crismon, M, Smith, T, Buckley, PF. Schizophrenia. In: DiPiro, JT, Yee, GC, Posey, L, Haines, ST, Nolin, TD, Ellingrod, V, eds. Pharmacotherapy: A Pathophysiologic Approach, 11th ed. McGraw Hill; 2020:1091-1124.
Google Scholar5. Diagnostic and Statistical Manual of Mental Disorder , Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Association; 2013.
Google Scholar6. Keepers, GA, Fochtmann, LJ, Anzia, JM, et al. The American Psychiatric Association Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901.
Google Scholar | Crossref | Medline7. Chien, WT, Mui, JH, Cheung, EF, Gray, R. Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial. Trials. 2015;16:270. doi:10.1186/s13063-015-0785-z.
Google Scholar | Crossref | Medline8. Rowland, TA, Marwaha, S. Epidemiology and risk factors for bipolar disorder. Ther Adv Psychopharmacol. 2018;8(9):251-269. doi:10.1177/2045125318769235.
Google Scholar | SAGE Journals | ISI9. Bipolar Disorder . Bethesda, MD: National Institute of Mental Health, U.S. Department of Health and Human Services. Accessed June 24, 2021. https://www.nimh.nih.gov/health/topics/bipolar-disorder/.
Google Scholar10. Clinical Guideline for Bipolar Disorder Assessment and Management . National Institute for Health and Care Excellence. Published September 24, 2014. Updated February 11, 2020. Accessed October 20, 2021. https://www.nice.org.uk/guidance/cg185.
Google Scholar11. Komossa, K, Rummel-Kluge, C, Hunger, H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010; 3:CD006654. doi:10.1002/14651858.CD006654.pub2.
Google Scholar | Crossref12. Citrome, L, Graham, C, Simmons, A, et al. An evidence-based review of OLZ/SAM for treatment of adults with schizophrenia or bipolar I disorder. Neuropsychiatric Disease and Treatment. 2021;17:2885. doi:10.2147/NDT.S313840.
Google Scholar | Crossref13. Package insert . Lybalvi (olanzapine/samidorphan) tablet. Waltham, MA: Alkermes, May 2021.
Google Scholar14. Sun, L, Barter, Z, von Moltke, L, Rowland Yeo, K. Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet. CPT Pharmacometrics Syst Pharmacol. 2021;10(9):1071-1080. doi:10.1002/psp4.12675.
Google Scholar | Crossref | Medline15. Gaffney, A . An increasing number of companies are using a once-obscure FDA drug approval pathway. Regulatory Affairs Professionals Society (RAPS). doi:10.1177/1741134320987866.
Google Scholar | Crossref16. Potkin, SG, Kunovac, J, Silverman, BL, et al. Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, Phase 3 ENLIGHTEN-1 Study. J Clin Psychiatry. 2020;81(2):19m12769. doi:10.4088/JCP.19m12769.
Google Scholar | Crossref | Medline17. Correll, CU, Newcomer, JW, Silverman, B, et al. Effects of Olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry, 2020;12(177):1168-1178. doi:10.1176/appi.ajp.2020.19121279.
Google Scholar | Crossref18. Kahn, RS, Silverman, BL, DiPetrillo, L, et al. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: results from the ENLIGHTEN-2 long-term extension. Schizophr Res. 2021;232:45-53. doi:10.1016/j.schres.2021.04.009.
Google Scholar | Crossref | Medline19. Sun, L, Yagoda, S, Yao, B, Graham, C, von Moltke, L. Combination of olanzapine and samidorphan has no clinically significant effect on the pharmacokinetics of lithium or valproate. Clin Drug Investig. 2020;40(1):55-64. doi:10.1007/s40261-019-00860-y.
Google Scholar | Crossref | Medline20. GoodRx . Lybalvi pricing, coupons, and savings. Accessed October 24, 2021. https://m.goodrx.com/lybalvi.
Google Scholar21. Package insert . Zyprexa (olanzapine) tablet. Indianapolis, IN: Eli Lilly, March 2009.
Google Scholar22. Martin, WF, Correll, CU, Weiden, PJ, et al. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry. 2019;176(6):457-467.
Google Scholar | Crossref | Medline23. National Library of Medicine . Naltrexone for antipsychotic-induced weight gain. Identifier NCT01866098. May 2013–April 2019, https://clinicaltrials.gov/ct2/show/NCT01866098.
Google Scholar24. Tek, C, Ratliff, J, Reutenauer, E, Ganguli, R, O’Malley, SS. A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept. J Clin Psychopharmacol. 2014;34(5):608-612. doi:10.1097/JCP.0000000000000192.
Google Scholar | Crossref | Medline25. de Silva, VA, Suraweera, C, Ratnatunga, SS, Dayabandara, M, Wanniarachchi, N, Hanwella, R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341. doi:10.1186/s12888-016-1049-5.
Google Scholar | Crossref | Medline26. Winklbaur, B, Ebner, N, Sachs, G, Thau, K, Fischer, G. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci. 2006;8(1):37-43. doi:10.31887/DCNS.2006.8.1/bwinklbaur.
Google Scholar | Crossref | Medline27. Cerullo, MA, Strakowski, SM. The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy. 2007;2:29. doi:10.1186/1747-597X-2-29.
Google Scholar | Crossref | Medline | ISI28. Pahwa, M, Sleem, A, Elsayed, OH, Good, ME, El-Mallakh, RS. New antipsychotic medications in the last decade. Curr Psychiatry Rep. 2021;23(12):87. doi:10.1007/s11920-021-01298-w.
Google Scholar | Crossref | Medline29. Yagoda, S, Graham, C, Simmons, A, Arevalo, C, Jiang, Y, McDonnell, D. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. CNS Spectr. 2021;26(4):383-392.
Google Scholar | Crossref | Medline30. Srisurapanont, M, Suttajit, S, Likhitsathian, S, Maneeton, B, Maneeton, N. A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine. Sci Rep. 2021;11(1):7583. doi:10.1038/s41598-021-87285-w.
Google Scholar | Crossref | Medline31. Paik, J . Olanzapine/samidorphan: first approval. Drugs. 2021;81(12):1431-1436. doi:10.1007/s40265-021-01568-0.
Google Scholar | Crossref | Medline